La Jolla Pharmaceutical Company Announces Share Repurchase Plan
November 17 2021 - 8:00AM
Business Wire
La Jolla Pharmaceutical Company (Nasdaq: LJPC) today announced
that it will commence a share repurchase plan for up to $10 million
of the Company’s common stock. Repurchases may be made from time to
time at the Company’s discretion. The plan has no time limit and
can be discontinued at any time. There can be no assurance as to
the timing or number of shares of any repurchases.
“The decision to repurchase shares reflects our confidence in
our team and the ability to execute against our strategic
initiatives for growth, which is supported by the strength of our
balance sheet,” said Larry Edwards, President and Chief Executive
Officer of La Jolla.
About La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company is dedicated to the
commercialization of innovative therapies that improve outcomes in
patients suffering from life-threatening diseases. GIAPREZA™
(angiotensin II) injection is approved by the FDA as a
vasoconstrictor indicated to increase blood pressure in adults with
septic or other distributive shock. XERAVA™ (eravacycline) for
injection is approved by the FDA as a tetracycline class
antibacterial indicated for the treatment of complicated
intra-abdominal infections (cIAI) in patients 18 years of age and
older. For more information, please visit www.ljpc.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211117005448/en/
Michael Hearne Chief Financial Officer La Jolla Pharmaceutical
Company (617) 715-3598 mhearne@ljpc.com
La Jolla Pharmaceutical (NASDAQ:LJPC)
Historical Stock Chart
From Jun 2024 to Jul 2024
La Jolla Pharmaceutical (NASDAQ:LJPC)
Historical Stock Chart
From Jul 2023 to Jul 2024